Remdesivir therapy in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorReddy Vegivinti, Charan Thej-
Autor(es): dc.creatorPederson, John M.-
Autor(es): dc.creatorSaravu, Kavitha-
Autor(es): dc.creatorGupta, Nitin-
Autor(es): dc.creatorBarrett, Averi-
Autor(es): dc.creatorDavis, Amber R.-
Autor(es): dc.creatorKallmes, Kevin M.-
Autor(es): dc.creatorEvanson, Kirk W.-
Data de aceite: dc.date.accessioned2026-02-09T11:16:18Z-
Data de disponibilização: dc.date.available2026-02-09T11:16:18Z-
Data de envio: dc.date.issued2021-01-13-
Data de envio: dc.date.issued2021-01-13-
Data de envio: dc.date.issued2021-01-
Fonte completa do material: dc.identifierhttps://repositorio.ufla.br/handle/1/45996-
Fonte completa do material: dc.identifierhttps://www.sciencedirect.com/science/article/pii/S2049080120305689-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1137297-
Descrição: dc.descriptionPurpose To perform a systematic review and meta-analysis of randomized controlled trials that examined remdesivir treatment for COVID-19. Materials and methods A systematic literature search was performed using Pubmed, Embase, and ClinicalTrials.gov to identify studies published up to October 25, 2020 that examined COVID-19 treatment with remdesivir. A total of 3 randomized controlled trials that consisted of 1691 patients were included in the meta-analysis. Results The odds for mechanical ventilation (MV) or extracorporeal membrane oxygenation (ECMO) following treatment was significantly lower in the remdesivir group compared to the control group (OR = 0.48 [95% CI: 0.34; 0.69], p < 0.001). The odds of early (at day 14/15; OR = 1.42 [95% CI: 1.16; 1.74], p < 0.001) and late (at day 28/29; OR = 1.44 [95% CI: 1.16; 1.79], p = 0.001) hospital discharge were significantly higher in the remdesivir group compared to the control group. There was no difference in the odds for mortality in patients treated with remdesivir (OR = 0.77 [95% CI: 0.56; 1.06], p = 0.108). Conclusions Remdesivir attenuates disease progression, leading to lower odds of MV/ECMO and greater odds of hospital discharge for COVID-19 patients. However, remdesivir does not affect odds of mortality.-
Idioma: dc.languageen-
Publicador: dc.publisherElsevier-
Direitos: dc.rightsrestrictAccess-
???dc.source???: dc.sourceAnnals of Medicine and Surgery-
Palavras-chave: dc.subjectCOVID-19-
Palavras-chave: dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-
Palavras-chave: dc.subjectAntiviral agents-
Título: dc.titleRemdesivir therapy in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials-
Tipo de arquivo: dc.typeArtigo-
Aparece nas coleções:Repositório Institucional da Universidade Federal de Lavras (RIUFLA)

Não existem arquivos associados a este item.